技术评估：CpG-7909，科利公司。
Technology evaluation: CpG-7909, Coley.
作者信息
Paul Stéphane
机构信息
Transgene SA, 2 Rue Adolphe Hirn, Strasbourg 67082, France.
出版信息
Curr Opin Mol Ther. 2003 Oct;5(5):553-9.
Coley Pharmaceutical (formerly CpG ImmunoPharmaceuticals) is developing CpG-7909 (ProMune) for use in the potential treatment of cancer and as a vaccine adjuvant. By April 2000, CpG-7909 had entered phase I/II trials for cancer and in March 2002, Coley initiated a phase I trial in non-Hodgkin's lymphoma in combination with rituximab (Rituxan). By October 2002, CpG-7909 was in phase II trials as a vaccine adjuvant. Cpg-7909 is currently also undergoing phase II trials for melanoma.
科利制药公司（前身为CpG免疫制药公司）正在研发CpG-7909（ProMune），用于癌症的潜在治疗以及作为疫苗佐剂。到2000年4月，CpG-7909已进入癌症的I/II期试验，2002年3月，科利公司启动了一项与利妥昔单抗（美罗华）联合用于非霍奇金淋巴瘤的I期试验。到2002年10月，CpG-7909作为疫苗佐剂进入II期试验。CpG-7909目前也正在进行黑色素瘤的II期试验。
Zotero 插件